AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...
Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
"The US verdicts resonate in Hong Kong, which follows international human rights standards, yet our public conversations ...
It’s an age-old story: an innovative robot company with a brilliant idea and some game-changing technology finds itself ...
UK based provider of physical layer IP for 5G non-terrestrial networks (NTN), AccelerComm Ltd, today announced the grant of its 56th international patent, marking a significant milestone as the ...
This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...
Tempus AI TEM shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results